Table 1.
Summary of patient data.
| Sex | Age (yrs) | Time (yrs)a | WBC (× 106/ml) | Stageb | CD38 (%) | β2mc | FISH | Txd | LDT (mos)e | Δp-STAT3f | ΔHMGRg | LDL (mM) | Chol (MFI) | Statin use | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group 1 (n = 18) | 0.5h | 67.7 ± 2.3j | 9.6 ± 1.2 | 73 ± 4.9 | 2.7 ± 0.3 | 5.2 ± 1.7 | 3.6 ± 0.5 | 4/9i | 0.8 ± 0.3 | 53.6 ± 10.4 | 1.3 ± 0.18 | − 0.24 ± 0.07 | 2.38 ± 0.24 | NA | 11/18 |
| Group 2 (n = 11) | 0.45 | 65.7 ± 2.5 | 11.9 ± 2.8 | 140.6 ± 44.3 | 2.7 ± 0.4 | 7.7 ± 3.5 | 4.2 ± 1.0 | 3/7 | 0.8 ± 0.4 | 12.6 ± 1.7 | 0.17 ± 0.07 | 0.25 ± 0.07 | 2.47 ± 0.26 | NA | 6/11 |
| ⁎ | ⁎⁎ | ⁎⁎ | ⁎⁎ | ||||||||||||
| Group A (n = 9) | 0.55 | 70.7 ± 5.2 | 10.6 ± 1.7 | 154.5 ± 40.9 | 3.4 ± 0.3 | 6.2 ± 2.7 | 5.0 ± 1.3 | 3/8 | 1.3 ± 0.4 | 29.3 ± 9.7 | 2.1 ± 0.2 | 9.5 ± 2.7 | no | ||
| Group B (n = 10) | 0.8 | 66 ± 2.2 | 9.8 ± 2.0 | 86.5 ± 34.9 | 3.6 ± 0.2 | 7.1 ± 3.1 | 3.5 ± 0.4 | 1/6 | 0.8 ± 0.3 | 31.6 ± 8.0 | 3.4 ± 0.3 | 658.8 ± 283.9 | no | ||
| Statin use (n = 11) | 0.55 | 77.5 ± 4.2 | 8.8 ± 1.1 | 64.7 ± 20.8 | 2.9 ± 0.5 | 18.3 ± 9.2 | 3.8 ± 0.5 | 2/7 | 1.0 ± 0.4 | 46.0 ± 13.0 | 2.2 ± 0.2 | 83.2 ± 53.5 | yes | ||
| ⁎ | ⁎ | ⁎ | ⁎⁎⁎ | ⁎ |
NA = not available.
Time since diagnosis.
Rai stage 0 = lymphocytosis, 1 = with adenopathy, 2 = with hepatosplenomegaly, 3 = with anemia, 4 = with thrombocytopenia.
Normal range:0.6–23 μg/ml.
Number of treatments including alkylator and fludarabine regimens, splenectomy, and Ibrutinib.
Lymphocyte doubling time in months.
Difference between densitometric values for pSTAT3 normalized to beta-actin in activated CLL cells with and without LDL supplementation (0.5 mM) after 18 h.
Difference between HMGCoA-reductase mRNA transcripts in the presence or absence of LDLs after 18 h.
Ratio of males to females.
Number of intermediate/high-risk cytogenetic lesions: deletion 17p, deletion 11q, trisomy 12 (T12).
Average ± standard error.
p < 0.05.
p < 0.001.
p < 0.005.